OUR AIM
We passionately join cancer patients in their fight for effective, safe, non-toxic cancer treatments that increase quality of life and survival. As a weapon, we are developing viral immunotherapy which has the potential to drastically improve the clinical treatment of solid tumours and their metastases.
OUR TECHNOLOGY
Since the turn of the 20th century there has been increasing evidence that cancer patients who contract a viral infection can undergo periods of clinical remission. However, researchers had struggled for decades to safely and effectively harness this power. Now we enter a new dawn where viruses can be engineered to replicate selectively in tumours, destroy malignant cells and reprogram our immune system to respond to a broad range of solid tumours. We have used "biological intelligence" to optimise our viruses for therapeutic use in man.
OUR APPROACH
Overcoming barriers for systemic delivery Therapeutic viruses have huge potential yet cannot currently be delivered intravenously, being limited to intratumoral injection. This restricts their clinical use.
Our pioneering platform is designed to relieve this crucial barrier that prevents systemic delivery. This allows our cancer-killing virus to deliver medicinal payloads within the tumour to stimulate and reprogram the immune system to attack and destroy cancer.
OUR TEAM
Expertise you can trust, backed by a proven track record of consistent and successful project delivery
Dr Chris Ullman
CEO
Antonio Postigo
CSO
Priya Mande
Chairman
Laura Fletcher
Director
Dr Chris Ullman
CEO
Over 20 years experience in biotech, leading teams. Team leader at Gendaq, CSO/CEO at Isogenica. Consultant in molecular evolution, peptide, antibody discovery and delivery technologies.
Antonio Postigo
CSO
18 years of experience researching oncolytic viruses and has held roles of increasing seniority in academia. Ex-Head of Molecular Virology at PsiOxus, a leading oncolytic virus company.
Priya Mande
Chairman
Priya is an experienced CEO, COO, Board Director & Company Secretary. Fellow of the U.K. Institute of Directors. COO, CEO and UK President of Akamis Bio. Dep. Director of HMG Vaccine Taskforce, and has held senior positions at PowderMed, GSK, Pfizer. Priya Mande attended London Business School
Laura Fletcher
Director
Head of BD and Strategic Alliances in Therapeutics at Deep Science Ventures, ex Associate Director of Cancer Research UK’s Commercial Partnerships team. Extensive experience in oncology deal-making, including transacting licences, collaboration and spin-outs.
LATEST NEWS
Explore our news section for the latest in hearing care. Stay updated on breakthroughs, tips, and expert insights to support your journey to better hearing health.
UPDATE
Stratosvir Awarded UK Germany Bilateral Collaborative R&D Grant from Innovate UK
INVESTMENT
Stratosvir Receives Investment from UK Cancer Organisations
INVESTMENT
o2h Ventures Invests in Stratosvir – Advancing Viral Immunotherapy For Late-Stage Cancer
CONTACT US
STRATOSVIR LIMITED,
incorporated in ENGLAND and WALES.
Registered Office : 46-54 High Street, Ingatestone, England, CM4 9DW.
Stevenage Bioscience Catalyst : SG1 2FX, Stevenage, Hertfordshire, England, United Kingdom
Company Number : 13099988.
VAT Registration Number : 380 3574 92
Email : [email protected]